JUPITER LIFE LINE HOSP L
JLHL · General/Diversified · NSE
₹1,291
Current Market Price
Fair Value (DCF)
₹546
Margin of Safety
-57.7%
Updated 3d ago
YieldIQ Score
53/100
Piotroski F-Score
5/9
Economic Moat
Wide
Confidence
45%
ROE
—
Debt/Equity
0.28
WACC
11.1%
Market Cap
₹8,464 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
14.9%
Return on capital employed
EV / EBITDA
26.8×
Enterprise multiple
Debt / EBITDA
1.3×
Leverage vs earnings
Interest Coverage
76.4×
EBIT covers interest
Current Ratio
4.51×
Short-term liquidity
Asset Turnover
0.66×
Revenue per ₹ of assets
Revenue CAGR (3Y)
19.7%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,290.9
Bear case
₹296.1
MoS -336.0%
Base case
₹545.77
MoS -136.5%
Bull case
₹613.75
MoS -110.3%
Ratio Trends
JLHL · last 4 annual periods
ROE
14.3%
ROCE
18.2%
Operating Margin
—
Debt / Equity
0.29×
PE
—
EV / EBITDA
—
Historical Financials
JLHL · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹733 Cr | ₹893 Cr | ₹290 Cr | ₹1256 Cr | +19.7% |
| EBITDA | ₹150 Cr | ₹206 Cr | ₹260 Cr | ₹318 Cr | +28.5% |
| EBIT | — | — | ₹63.1 Cr | — | +0.0% |
| PAT | ₹51.1 Cr | ₹72.9 Cr | ₹45.3 Cr | ₹194 Cr | +55.8% |
| EPS (diluted) | — | — | ₹6.49 | — | +0.0% |
| CFO | ₹137 Cr | ₹117 Cr | ₹115 Cr | ₹253 Cr | +22.7% |
| CapEx | ₹-91.7 Cr | ₹-77.2 Cr | — | ₹-321 Cr | — |
| FCF | ₹45.2 Cr | ₹39.9 Cr | — | ₹-67.4 Cr | — |
| Total Assets | ₹909 Cr | ₹986 Cr | ₹1281 Cr | ₹1905 Cr | +28.0% |
| Total Debt | ₹495 Cr | ₹469 Cr | ₹0.0 Cr | ₹393 Cr | -7.4% |
| Shareholders' Equity | ₹288 Cr | ₹364 Cr | ₹1169 Cr | ₹1356 Cr | +67.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
JLHL vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| HCG HCG | — | — | Pending | 4.5% | — |
| JSLL JSLL | — | — | Pending | 33.2% | — |
| PARKHOSPS PARK MEDI WORLD LIMITED | -54.6% | 46 | Overvalued | 18.2% | — |
| YATHARTH YATHARTH | — | — | Pending | 8.0% | — |
| NEPHROPLUS NEPHROPLUS | — | — | Pending | 11.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for JLHL in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of JLHL →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for JLHL →
Compare
Head-to-head with peers
Compare JLHL side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse JLHLNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.